Beyond Funding: Metrics for Enterprise Health AI Velocity

The venture capital world is flooded with AI health startups, and every one of them promises to change the world and deliver huge returns. But in the rush to get a press release out about a new funding round, there’s a distinction that gets lost: the difference between cash in the bank and actual, sustainable velocity at the enterprise level. A big funding announcement tells you what investors were excited about six months ago. It’s a lagging indicator of market penetration and operational scale. For investors who need to benchmark their early-to-mid-stage companies, you need a stronger, metrics-driven framework to see which enterprise health AI players are actually winning.

Beyond Funding: Defining Enterprise Health AI Velocity

If you really want to gauge the scale and speed of an enterprise health AI company, you have to look past the funding headlines and find real expansion signals. At aihealth100.com, our entire editorial mission is built on growth-metrics analysis, which means we track employer and health-plan expansion, the depth of enterprise contracts, and we make the case that the best AI health companies are actually accelerating as regulatory scrutiny gets tougher. This demands a playbook that ignores anecdotal hype and focuses on verifiable, structural signs of market adoption and regulatory seriousness. We track health-plan relationships, Fortune 500 deployments, and the volume of covered lives as the key signals, using a company like Hello Heart’s path as a benchmark for profiling its competitors. For example, a company landing and then expanding a contract with a major health plan translates directly into covered lives and recurring revenue, which is a far more reliable signal than a Series B press release.

Case Studies in Enterprise Scale: Tempus AI and Abridge

A look at companies like Tempus AI and Abridge gives a much clearer picture of what real growth velocity looks like in this sector.

Tempus AI: Using Regulatory Pathways for Revenue Growth

Tempus AI’s growth comes from a smart two-part strategy: build something clinically useful and master the regulatory game. Their whole approach to AI-driven precision medicine, especially in cancer care, uses FDA-approved companion diagnostics. This is a strategic move that drives enterprise revenue. When your AI is tied to a diagnostic that has FDA 510(k) clearance and directly guides treatment, it massively de-risks adoption for big health systems and payers. Being able to show an FDA clearance for your SaMD (FDA definition of Software as a Medical Device) is gold in a field where everyone is tired of unregulated AI hype. Now that they’re publicly traded on Nasdaq as of June 2024, Tempus AI’s SEC-reported revenue growth shows this strategy is working, with Q1 2026 revenue jumping 36.1% year-over-year to $348.1 million and Q2 2026 revenue climbing 22% year-over-year to $382.5 million. The company is even guiding for full-year 2026 revenue of around $1.59 billion to $1.60 billion, which is about 25% annual growth. Their growth is about embedding their AI into the clinical workflow through validated, reimbursable pathways. This makes their enterprise contracts deeper and stickier because hospitals and oncology networks begin to see Tempus as a core part of patient care. The growth in these deployments signals sustained use, not just a one-time sale, which is what investors should be looking for.

Abridge: Scaling Through Clinical Documentation Integration

Abridge, on the other hand, gets its velocity from making itself indispensable inside existing clinical documentation workflows. Its AI tool summarizes medical conversations, tackling the massive administrative burden that burns out clinicians. For Abridge, scaling health system contracts is all about showing a clear ROI by lowering physician burnout and making documentation more accurate. You can see their market penetration in their deployment counts. The platform is now in use across more than 300 enterprise health systems and supports over 100 million patient-clinician conversations a year as of August 2026. Every new health system contract is a major expansion signal, especially the ones that involve deep integration into the electronic health record (EHR). This is a foundational integration that becomes incredibly sticky, not some bolt-on app nobody uses. The speed at which Abridge moves customers from small pilot programs to system-wide rollouts says a lot about its growth trajectory. This level of integration doesn’t happen without serious adherence to HIPAA and SOC 2 Type II compliance which tells you you’re dealing with a mature and trustworthy enterprise partner. HITRUST vs. SOC 2 for healthcare vendors

The Investment Playbook: Three Core Metrics for Valuation

Venture capital partners and growth equity investors need a clear playbook. Forget the innovation buzz for a second and focus on these three core metrics to find the real scale and velocity of an enterprise health AI company:

1. Annual Recurring Revenue (ARR) and Contract Expansion Rate

Funding is a vanity metric. ARR is sanity. While funding announcements are lagging indicators, ARR gives you a real-time read on commercial success. But don’t just look at the absolute ARR number. The contract expansion rate gives you much deeper insight because it measures growth from your existing customers, which is the strongest signal of product-market fit and satisfaction you can get. A high expansion rate means a company’s initial wedge product is working and leading to bigger deployments and more covered lives within a health system or payer network. You should be looking for multi-year contracts and clear evidence that customers are buying additional AI modules. Companies that have built a strong data moat to protect their proprietary data and model performance are in the best position for long-term ARR growth.

2. Clinical Validation and Regulatory Momentum

In health AI, clinical validation is everything, and regulatory momentum is a massive accelerator. As Eric Topol says all the time, AI in medicine has to meet very high standards. Investors need to dig in and see if a company’s AI is backed by peer-reviewed clinical studies that prove it’s effective and safe. Regulatory clearances like an FDA 510(k) or a De Novo classification are commercial enablers, not just boxes to tick. A company that has a clear regulatory strategy, and maybe even a Breakthrough Device Designation, is showing a commitment to patient safety and has a much less risky path to market and reimbursement. And when you see that a company has secured CPT codes (Category I or III) for its AI service, that’s a huge tell for future reimbursement and market-wide adoption. AMA CPT Code application process

3. Health Plan and Fortune 500 Deployment Depth

The real test of enterprise scale is how deeply a company is deployed within health plans and Fortune 500 employers. This means you have to track the volume of covered lives the AI solution touches, not just the number of contracts. A company can have a dozen small contracts, but true scale is when you land a large-scale deployment covering millions of people. Are they covering 10,000 lives in a pilot or 2 million lives across an entire health plan’s population? That’s the question. This metric tells you how much of the total addressable market (TAM) the company is actually capturing and whether they can handle a complex enterprise sales cycle. For health plans, you want to see the AI integrated into core functions like utilization management or chronic disease programs. For employers, you look for adoption in wellness or benefits programs. Companies that have a clear ROI model for these big buyers are the ones that will grow the fastest.

The Increasing Importance of Regulatory Maturity

It’s not a coincidence that the most validated AI health companies are growing faster just as regulators are getting more involved. The FDA, the American Medical Association, and others are putting out frameworks like GMLP (Good Machine Learning Practice) and making it clear they expect a strong QMS and things like ISO 13485 certification. This increased scrutiny is a problem for some, but it’s a huge competitive advantage for companies that built their products from day one with compliance and clinical evidence in mind. Hippocratic AI, for example, just closed a $126 million Series C in November 2025, bringing its total funding to $404 million at a $3.5 billion valuation, and it will have to clear these same hurdles to scale its business and justify that number. The companies that treat regulatory compliance as part of the product, not a chore to be done later, are the ones that land the big enterprise contracts and accelerate their growth. They build trust, and you can’t build a long-term business in healthcare without it. Our analysis is based on public data like SEC disclosures for companies like Tempus AI and verified press announcements about contracts for companies like Abridge. We cross-reference everything with FDA databases and peer-reviewed studies to make sure our growth metrics are solid. This multi-variable analysis gives investors a strong framework for spotting the real momentum players in this fast-moving sector.